Table 2.
Fold changes of molecular apocrine-signature genes following treatment with AR and MEK inhibitors.
| Tx Gene |
MDA-CI-2 | MDA-FLU | MDA-FLU-CI | MDA-CI-10 | HCC-CI-2 | HCC-FLU | HCC-FLU-CI | HCC-CI-10 |
|---|---|---|---|---|---|---|---|---|
| PIP | 0.71 | 0.63 | 0.24 | 0.19 | 0.65 | 0.4 | 0.26 | 0.42 |
| DUSP6 | 0.6 | 0.125 | 0.01 | 0.01 | 0.16 | 0.98 | 0.18 | 0.02 |
| S100A8 | 1.2 | 0.09 | 0.06 | 0.45 | 1.3 | 0.86 | 0.77 | 0.68 |
| FOXA1 | 1.2 | 0.67 | 0.5 | 0.9 | 1.08 | 0.71 | 0.58 | 0.68 |
| TFAP2 | 1 | 0.43 | 0.15 | 0.5 | 1.61 | 0.53 | 0.68 | 1.69 |
| SOX11 | 1.3 | 0.56 | 0.32 | 0.63 | 1.97 | 1 | 1.95 | 2.33 |
| BANP | 1 | 0.78 | 0.9 | 1 | 1.16 | 0.94 | 1.09 | 1.07 |
| PER2 | 1.27 | 0.85 | 1.62 | 1.74 | 0.93 | 0.79 | 0.9 | 0.59 |
| TFF3 | 1.71 | 0.55 | 0.43 | 0.73 | 1.23 | 1.23 | 1.72 | 1.43 |
| AZGP1 | 1.36 | 1.29 | 0.73 | 1 | 1.3 | 1.78 | 2.23 | 1.21 |
* The average fold change to control for three biological replicate experiments is shown for each treatment group. Tx, treatment group; MDA, MDA-MB-453 and HCC, HCC-1954. FLU, flutamide at 25 µM and 40 µM concentrations for MDA-MB-453 and HCC-1954, respectively. CI-2, CI-1040 at 2 µM and CI-10: CI-1040 at 10 µM. Standard deviation of the fold changes: <0.05.